Cargando…

Proton beam therapy combined with retrograde intra-arterial infusion chemotherapy for an extremely rapid growing recurrent ameloblastic carcinoma: A case report

Ameloblastic carcinoma (AC) is a very rare malignant odontogenic tumor. Although surgical resection is generally performed, treatment approaches have not been established for recurrent cases. Chemotherapy and radiotherapy are positioned as adjunctive therapies, and few studies investigated definitiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Takayama, Kanako, Nakamura, Tatsuya, Takada, Akinori, Kato, Takahiro, Sakuma, Hideo, Mitsudo, Kenji, Fuwa, Nobukazu, Murakami, Masao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412713/
https://www.ncbi.nlm.nih.gov/pubmed/32802330
http://dx.doi.org/10.3892/mco.2020.2104
_version_ 1783568667434287104
author Takayama, Kanako
Nakamura, Tatsuya
Takada, Akinori
Kato, Takahiro
Sakuma, Hideo
Mitsudo, Kenji
Fuwa, Nobukazu
Murakami, Masao
author_facet Takayama, Kanako
Nakamura, Tatsuya
Takada, Akinori
Kato, Takahiro
Sakuma, Hideo
Mitsudo, Kenji
Fuwa, Nobukazu
Murakami, Masao
author_sort Takayama, Kanako
collection PubMed
description Ameloblastic carcinoma (AC) is a very rare malignant odontogenic tumor. Although surgical resection is generally performed, treatment approaches have not been established for recurrent cases. Chemotherapy and radiotherapy are positioned as adjunctive therapies, and few studies investigated definitive non-operative therapy. We present the case of a 71-year-old male with recurrent secondary-type AC arising from the right maxilla, who was treated with proton beam therapy (PBT; 71.4 Gy relative biological effectiveness in 32 fractions) combined with continuous intra-arterial infusion of cisplatin (40 mg/m(2)) and docetaxel (8 mg/m(2)). The patient experienced acute grade 3 mucositis, dermatitis and neutropenia, which were resolved within 3 months of treatment. Late adverse events were grade 1 skin atrophy, and grade 2 right optic nerve disorder and retinopathy. After ~8 years of treatment, the patient died from another cause but did not experience any relapse or metastasis during the follow-up period of 94 months. To the best of our knowledge, this is the first report of recurrent AC treated with PBT and intra-arterial infusion chemotherapy without any severe late adverse events. This combination therapy approach may be considered as an effective therapeutic option for inoperable AC.
format Online
Article
Text
id pubmed-7412713
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-74127132020-08-14 Proton beam therapy combined with retrograde intra-arterial infusion chemotherapy for an extremely rapid growing recurrent ameloblastic carcinoma: A case report Takayama, Kanako Nakamura, Tatsuya Takada, Akinori Kato, Takahiro Sakuma, Hideo Mitsudo, Kenji Fuwa, Nobukazu Murakami, Masao Mol Clin Oncol Articles Ameloblastic carcinoma (AC) is a very rare malignant odontogenic tumor. Although surgical resection is generally performed, treatment approaches have not been established for recurrent cases. Chemotherapy and radiotherapy are positioned as adjunctive therapies, and few studies investigated definitive non-operative therapy. We present the case of a 71-year-old male with recurrent secondary-type AC arising from the right maxilla, who was treated with proton beam therapy (PBT; 71.4 Gy relative biological effectiveness in 32 fractions) combined with continuous intra-arterial infusion of cisplatin (40 mg/m(2)) and docetaxel (8 mg/m(2)). The patient experienced acute grade 3 mucositis, dermatitis and neutropenia, which were resolved within 3 months of treatment. Late adverse events were grade 1 skin atrophy, and grade 2 right optic nerve disorder and retinopathy. After ~8 years of treatment, the patient died from another cause but did not experience any relapse or metastasis during the follow-up period of 94 months. To the best of our knowledge, this is the first report of recurrent AC treated with PBT and intra-arterial infusion chemotherapy without any severe late adverse events. This combination therapy approach may be considered as an effective therapeutic option for inoperable AC. D.A. Spandidos 2020-10 2020-07-30 /pmc/articles/PMC7412713/ /pubmed/32802330 http://dx.doi.org/10.3892/mco.2020.2104 Text en Copyright: © Takayama et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Takayama, Kanako
Nakamura, Tatsuya
Takada, Akinori
Kato, Takahiro
Sakuma, Hideo
Mitsudo, Kenji
Fuwa, Nobukazu
Murakami, Masao
Proton beam therapy combined with retrograde intra-arterial infusion chemotherapy for an extremely rapid growing recurrent ameloblastic carcinoma: A case report
title Proton beam therapy combined with retrograde intra-arterial infusion chemotherapy for an extremely rapid growing recurrent ameloblastic carcinoma: A case report
title_full Proton beam therapy combined with retrograde intra-arterial infusion chemotherapy for an extremely rapid growing recurrent ameloblastic carcinoma: A case report
title_fullStr Proton beam therapy combined with retrograde intra-arterial infusion chemotherapy for an extremely rapid growing recurrent ameloblastic carcinoma: A case report
title_full_unstemmed Proton beam therapy combined with retrograde intra-arterial infusion chemotherapy for an extremely rapid growing recurrent ameloblastic carcinoma: A case report
title_short Proton beam therapy combined with retrograde intra-arterial infusion chemotherapy for an extremely rapid growing recurrent ameloblastic carcinoma: A case report
title_sort proton beam therapy combined with retrograde intra-arterial infusion chemotherapy for an extremely rapid growing recurrent ameloblastic carcinoma: a case report
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412713/
https://www.ncbi.nlm.nih.gov/pubmed/32802330
http://dx.doi.org/10.3892/mco.2020.2104
work_keys_str_mv AT takayamakanako protonbeamtherapycombinedwithretrogradeintraarterialinfusionchemotherapyforanextremelyrapidgrowingrecurrentameloblasticcarcinomaacasereport
AT nakamuratatsuya protonbeamtherapycombinedwithretrogradeintraarterialinfusionchemotherapyforanextremelyrapidgrowingrecurrentameloblasticcarcinomaacasereport
AT takadaakinori protonbeamtherapycombinedwithretrogradeintraarterialinfusionchemotherapyforanextremelyrapidgrowingrecurrentameloblasticcarcinomaacasereport
AT katotakahiro protonbeamtherapycombinedwithretrogradeintraarterialinfusionchemotherapyforanextremelyrapidgrowingrecurrentameloblasticcarcinomaacasereport
AT sakumahideo protonbeamtherapycombinedwithretrogradeintraarterialinfusionchemotherapyforanextremelyrapidgrowingrecurrentameloblasticcarcinomaacasereport
AT mitsudokenji protonbeamtherapycombinedwithretrogradeintraarterialinfusionchemotherapyforanextremelyrapidgrowingrecurrentameloblasticcarcinomaacasereport
AT fuwanobukazu protonbeamtherapycombinedwithretrogradeintraarterialinfusionchemotherapyforanextremelyrapidgrowingrecurrentameloblasticcarcinomaacasereport
AT murakamimasao protonbeamtherapycombinedwithretrogradeintraarterialinfusionchemotherapyforanextremelyrapidgrowingrecurrentameloblasticcarcinomaacasereport